With the use of single agent anti-PD1, 40–50% of patients with advanced or metastatic melanoma will have an initial response to therapy, and overall, 30–40% of patients will have a long-term durable clinical benefit [4]. The gene discussed is PDCD1; the disease is metastatic melanoma.